Despite the success of its new weight loss drug Zepbound, Lilly's recent earnings failed to meet expectations.

But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost immediately.

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

A new study has found that Mounjaro may not only be good at treating diabetes, but could actually help prevent the disease.

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

BHB-Phe, a newly discovered compound, reduces appetite and body weight by activating specific brain neurons. Researchers from ...

Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...